IL139687A0 - USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS IN THE TREATMENT OF KIDNEY DISEASE - Google Patents

USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS IN THE TREATMENT OF KIDNEY DISEASE

Info

Publication number
IL139687A0
IL139687A0 IL13968799A IL13968799A IL139687A0 IL 139687 A0 IL139687 A0 IL 139687A0 IL 13968799 A IL13968799 A IL 13968799A IL 13968799 A IL13968799 A IL 13968799A IL 139687 A0 IL139687 A0 IL 139687A0
Authority
IL
Israel
Prior art keywords
inhibitors
tgf
treatment
kidney disease
integrin receptor
Prior art date
Application number
IL13968799A
Original Assignee
Boys Town Nat Res Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/292,534 external-priority patent/US6492325B1/en
Application filed by Boys Town Nat Res Hospital filed Critical Boys Town Nat Res Hospital
Priority claimed from PCT/US1999/011073 external-priority patent/WO1999061040A2/en
Publication of IL139687A0 publication Critical patent/IL139687A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL13968799A 1998-05-22 1999-05-19 USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS IN THE TREATMENT OF KIDNEY DISEASE IL139687A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8658798P 1998-05-22 1998-05-22
US8876698A 1998-06-02 1998-06-02
US15048598A 1998-09-09 1998-09-09
US09/292,534 US6492325B1 (en) 1998-05-22 1999-04-15 Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease
PCT/US1999/011073 WO1999061040A2 (en) 1998-05-22 1999-05-19 USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS IN THE TREATMENT OF KIDNEY DISEASE

Publications (1)

Publication Number Publication Date
IL139687A0 true IL139687A0 (en) 2002-02-10

Family

ID=27492055

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13968799A IL139687A0 (en) 1998-05-22 1999-05-19 USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS IN THE TREATMENT OF KIDNEY DISEASE
IL139687A IL139687A (en) 1998-05-22 2000-11-14 Use of ??1??1 integrin receptor inhibitors and tgf-??1 inhibitors for the preparation of pharmaceutical compositions for the treatment of kidney disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL139687A IL139687A (en) 1998-05-22 2000-11-14 Use of ??1??1 integrin receptor inhibitors and tgf-??1 inhibitors for the preparation of pharmaceutical compositions for the treatment of kidney disease

Country Status (2)

Country Link
IL (2) IL139687A0 (en)
IS (1) IS5718A (en)

Also Published As

Publication number Publication date
IS5718A (en) 2000-11-21
IL139687A (en) 2007-12-03

Similar Documents

Publication Publication Date Title
IL139030A0 (en) Therapeutic angiogenic factors and methods for their use
HUP0202048A2 (en) Use of alpha1betha1 integrin receptor inhibitors and tgf-betha1 inhibitors in the treatment of kidney disease
GB0109414D0 (en) Well treatment fluids and methods for the use thereof
HK1043625A1 (en) Kidney disease detection and treatment
GB0019302D0 (en) Biological materials and the use thereof for the treatment of disease
HUP0000963A3 (en) The use of levobupivacaine in paediatric surgery
PL352333A1 (en) Dihydrobenzodiazepines and use of same in treatment of dislipidemia
PL347542A1 (en) Therapeutic product and its use
IL139687A0 (en) USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS IN THE TREATMENT OF KIDNEY DISEASE
EP1322778A4 (en) Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
GB9822401D0 (en) Device for use in treatment of hair
HK1038886B (en) USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF KIDNEY DISORDER
AU8466601A (en) Methods of screening novel agents for use in cancer therapy and prevention
GB9903919D0 (en) Aminophenols and their therapeutic use
ID28817A (en) USE OF TETRAHIDROPIRIDIN (OR 4-HIDROPIPERIDIN) -BUTILAZOL DRUGS IN THE MAKING OF DRUGS FOR PAIN TREATMENT
HK1050315A1 (en) Conjugate for treating atheroma and other diseases
GB9907151D0 (en) Therapeutic antibody composition and use
GB9901682D0 (en) Therapeutic antibody composition and use
GB9901689D0 (en) Therapeutic antibody composition and use
GB9906754D0 (en) Therapeutic antibody composition and use
GB9810609D0 (en) Improvements in materials for medical and cosmetic use
AU140621S (en) Abalone and crayfish measure
GB0029613D0 (en) Biological materials and the use thereof in the treatment of disease
GB9823939D0 (en) Therapeutic antibody composition and use
GB9823931D0 (en) Therapeutic antibody composition and use

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed